Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For ReviewSeeking Alpha • Wednesday
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock UpsideBenzinga • 07/31/24
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For GalactosemiaSeeking Alpha • 05/29/24
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaGlobeNewsWire • 03/28/24
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsGlobeNewsWire • 03/06/24
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaGlobeNewsWire • 02/28/24
Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be PossibleSeeking Alpha • 02/16/24
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyGlobeNewsWire • 01/04/24
Applied Therapeutics: Multiple Inflection Points Could Generate Substantial ValueSeeking Alpha • 01/04/24
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7GlobeNewsWire • 11/01/23